FDA Withdraws Approval of TAZVERIK Cancer Drug at Manufacturer's Request
June 23, 2026
June 23, 2026
WASHINGTON, June 23 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has withdrawn approval of Epizyme Inc.'s, Cambridge, Massachusetts, TAZVERIK (tazemetostat) tablet, 200 milligrams, after the company requested removal of the drug's application and waived expedited withdrawal procedures.
The withdrawal took effect June 22, 2026, according to a notice published by HHS. TAZVERIK was approved on Jan. 23, 2020, under the accelerated ap . . .
The withdrawal took effect June 22, 2026, according to a notice published by HHS. TAZVERIK was approved on Jan. 23, 2020, under the accelerated ap . . .